Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTB323 in treatment-resistant generalized myasthenia gravis (Phase I/II, open-label)
jRCT2053240204Phase 2Suspended
- Sponsor
- Novartis
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rapcabtagene autoleucel in myasthenia gravis (MG), sponsored by Novartis. Primary endpoints: Safety and tolerability of YTB323 and Change in safety parameters from baseline. Started Jan 2025; status: suspended.
02
Drugs
rapcabtagene autoleucel
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2053240204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053240204.